Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent Herceptin® or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

NCT04109391 is registered in ClinicalTrials.gov with Tanvex BioPharma USA, Inc. as lead sponsor.

NCT NCT04109391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04109391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent Herceptin® or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03
Lead sponsor
Tanvex BioPharma USA, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 20, 2019
Completion date
March 8, 2022
Enrollment
338 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, early-stage breast cancer, her2-positive breast cancer, stage ii breast cancer, stage iiia breast cancer